Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11079679 | 0.90 | KDM1A (0.45) | KDM1AMEN1KMT2AHTR2ASIGMAR1 | |
| SCHEMBL9499577 | 0.89 | KDM1A (0.46) | KDM1AMEN1KMT2AHTR2ASIGMAR1 | |
| SCHEMBL7960703 | 0.82 | KDM1A (0.44) | KDM1AMEN1KMT2AHTR2ASIGMAR1 | |
| SCHEMBL19130231 | 0.82 | KDM1A (0.47) | KDM1AMEN1KMT2AHTR2ASIGMAR1 | |
| SCHEMBL6691850 | 0.82 | KDM1A (0.47) | KDM1AMEN1KMT2AHTR2ASIGMAR1 | |
| SCHEMBL4420303 | 0.79 | SIGMAR1 (0.49) | KDM1AMEN1KMT2AHTR2ASIGMAR1 | |
| SCHEMBL15891588 | 0.78 | CASP6 (0.45) | KDM1AMEN1KMT2AHTR2ASIGMAR1 | |
| SCHEMBL3896827 | 0.78 | SIGMAR1 (0.36) | KDM1AMEN1KMT2ASIGMAR1AKR1B1 | |
| SCHEMBL3910550 | 0.78 | KDM1A (0.53) | KDM1AHTR2ASIGMAR1HTR2C | |
| SCHEMBL6568570 | 0.78 | KDM1A (0.53) | KDM1ACYP3A4AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281854-A1 | MORPHOLINE COMPOUNDS | PFIZER INC | 2011-11-17 | — | — | US | disclosed |
| EP-1382333-B1 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | ASTELLAS PHARMA INC (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-7217706-B2 | Propanolamine derivatives | ASTELLAS PHARMA INC. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20040198791-A1 | Fused imidazole derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1403256-A1 | FUSED IMIDAZOLE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1382333-A2 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-6495546-B1 | SUCH AS 1-(N-BENZYL-N-(3-METHOXY-6,7,8,9-TETRAHYDRO-5H-BENZO-CYCLOHEPTEN-6-YL)AMINO)-3-PHENOXY-2-PROPANOL; ADRENERGIC RECEPTOR AGONISTS; ANTIULCEROUS, LIPOLYTIC, ANTIURINARY INCONTINENCE AND ANTIPOLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-20020120148-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| EP-0335375-B1 | ANTIHYPERLIPIDEMIC AND ANTIATHEROSCLEROTIC COMPOUNDS AND COMPOSITIONS | WARNER-LAMBERT COMPANY (US) | 1993-06-09 | — | — | EP | disclosed |
| US-5158948-A | Treating neurological and psychological disorders | ABBOTT LABORATORIES (US) | 1992-10-27 | — | — | US | disclosed |
| US-5030653-A | N-2,6-dialkyl- or n-2,6-dialkoxyphenyl-n-arylalkylurea compounds | WARNER-LAMBERT COMPANY (US) | 1991-07-09 | — | — | US | disclosed |
| US-4999373-A | Phenyl ureas or thioureas substituted with a xanthene or thioxanthene group | WARNER-LAMBERT COMPANY (US) | 1991-03-12 | — | — | US | disclosed |
| US-4948806-A | N-2,6-DIALKYL-OR N-2,6-DIALKOXYPHENYL-N'-ARYLALKYLUREA | WARNER-LAMBERT COMPANY (US) | 1990-08-14 | — | — | US | disclosed |
| EP-0179667-B1 | N6-SUBSTITUTED ADENOSINES | WARNER-LAMBERT COMPANY (US) | 1989-12-27 | — | — | EP | disclosed |
| US-4868210-A | PHENYL UREAS AND PHENYL THIOUREAS | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4791103-A | HYPOTENSIVE AGENTS, PSYCHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0179667-A2 | N6-substituted adenosines | WARNER-LAMBERT COMPANY (US) | 1986-04-30 | — | — | EP | disclosed |
| US-4473586-A | Aminoalkyl dihydronaphthalenes | ABBOTT LABORATORIES (US) | 1984-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281854-A1 | MORPHOLINE COMPOUNDS | REN, MC2R, NR3C2 | KDM1A 3924/4885MEN1 62/4885KMT2A 3182/4885 |
| US-20040198791-A1 | Fused imidazole derivative | H1-0, H1-5, H1-3 | KDM1A 2636/4885MEN1 1176/4885KMT2A 1203/4885 |
| US-20020120148-A1 | Propanolamine derivatives | AMY2A, PNMT, PNLIP | KDM1A 1212/4885MEN1 1043/4885KMT2A 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.